kras mutant cancer cell lines Search Results


oncospot kras g12c homozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have two alleles with G12C mutation of KRAS and puromycin marker in intron 2 of KRAS for selection. This cell line can be
   Buy from Supplier
homozygous sl753 cancer biomarker mutant cell lines  (Genecopoeia)
93
Genecopoeia homozygous sl753 cancer biomarker mutant cell lines
Homozygous Sl753 Cancer Biomarker Mutant Cell Lines, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kras+mutant+cancer+cell+lines/pmc12319893-118-4-14?v=Genecopoeia
Average 93 stars, based on 1 article reviews
homozygous sl753 cancer biomarker mutant cell lines - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
mutant kras  (ATCC)
93
ATCC mutant kras
(A) The TargetScan online database <t>(</t> <t>http://www.targetscan.org</t> ) predicted <t>KRAS</t> as an miR-193b target. The site between 1074 and 1080 (boxed region), one of the two predicted miR-193b binding sites in the 3′-UTR of KRAS, is shown, highlighting the evolutionarily conservation among humans (hsa), the chimpanzees (Ptr), rhesus monkey (Mml), bushbaby (Oga), and treeshrew (Tbe). (B) The two miR-193b binding sites at positions 303 to 309 and 1074–1080 in the KRAS 3′-UTR, identified using the TargetScan online database ( http://www.targetscan.org ), are shown. Seed sequences were mutated as shown in the boxed regions. The wild-type or mutant constructs were inserted into the pGL3 vector directly downstream of the luciferase gene. (C) 293A cells were co-transfected with miR-193b or scrambled oligonucleotide, wild-type or mutant firefly luciferase constructs of the KRAS 3′-UTR segment containing miR-193b binding sites, and Renilla luciferase (endogenous control). Luciferase activity was measured 24 hours after transfection using the Dual-Luciferase Reporter Assay Systems. Renilla-normalized luciferase activity is expressed relative to that obtained for the scrambled oligonucleotide under each condition. WT, wild-type; Mut, mutant. (D) KRAS and CCND1 protein levels were assessed by Western blotting 48 hours after transfection. (E) The protein levels of p-ERK and p-Akt were evaluated by Western blotting 48 hours after miR-193b transfection.
Mutant Kras, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kras+mutant+cancer+cell+lines/pmc04408116-137-28-35?v=ATCC
Average 93 stars, based on 1 article reviews
mutant kras - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
kras(g12d)  (Schmid GmbH)
90
Schmid GmbH kras(g12d)
(A) The TargetScan online database <t>(</t> <t>http://www.targetscan.org</t> ) predicted <t>KRAS</t> as an miR-193b target. The site between 1074 and 1080 (boxed region), one of the two predicted miR-193b binding sites in the 3′-UTR of KRAS, is shown, highlighting the evolutionarily conservation among humans (hsa), the chimpanzees (Ptr), rhesus monkey (Mml), bushbaby (Oga), and treeshrew (Tbe). (B) The two miR-193b binding sites at positions 303 to 309 and 1074–1080 in the KRAS 3′-UTR, identified using the TargetScan online database ( http://www.targetscan.org ), are shown. Seed sequences were mutated as shown in the boxed regions. The wild-type or mutant constructs were inserted into the pGL3 vector directly downstream of the luciferase gene. (C) 293A cells were co-transfected with miR-193b or scrambled oligonucleotide, wild-type or mutant firefly luciferase constructs of the KRAS 3′-UTR segment containing miR-193b binding sites, and Renilla luciferase (endogenous control). Luciferase activity was measured 24 hours after transfection using the Dual-Luciferase Reporter Assay Systems. Renilla-normalized luciferase activity is expressed relative to that obtained for the scrambled oligonucleotide under each condition. WT, wild-type; Mut, mutant. (D) KRAS and CCND1 protein levels were assessed by Western blotting 48 hours after transfection. (E) The protein levels of p-ERK and p-Akt were evaluated by Western blotting 48 hours after miR-193b transfection.
Kras(g12d), supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kras+mutant+cancer+cell+lines/10__1021_slash_acs__jcim__7b00343-223-31-19?v=Schmid+GmbH
Average 90 stars, based on 1 article reviews
kras(g12d) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
human colon cancer cell lines skco1 (kras mutant)  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection human colon cancer cell lines skco1 (kras mutant)
(A) The TargetScan online database <t>(</t> <t>http://www.targetscan.org</t> ) predicted <t>KRAS</t> as an miR-193b target. The site between 1074 and 1080 (boxed region), one of the two predicted miR-193b binding sites in the 3′-UTR of KRAS, is shown, highlighting the evolutionarily conservation among humans (hsa), the chimpanzees (Ptr), rhesus monkey (Mml), bushbaby (Oga), and treeshrew (Tbe). (B) The two miR-193b binding sites at positions 303 to 309 and 1074–1080 in the KRAS 3′-UTR, identified using the TargetScan online database ( http://www.targetscan.org ), are shown. Seed sequences were mutated as shown in the boxed regions. The wild-type or mutant constructs were inserted into the pGL3 vector directly downstream of the luciferase gene. (C) 293A cells were co-transfected with miR-193b or scrambled oligonucleotide, wild-type or mutant firefly luciferase constructs of the KRAS 3′-UTR segment containing miR-193b binding sites, and Renilla luciferase (endogenous control). Luciferase activity was measured 24 hours after transfection using the Dual-Luciferase Reporter Assay Systems. Renilla-normalized luciferase activity is expressed relative to that obtained for the scrambled oligonucleotide under each condition. WT, wild-type; Mut, mutant. (D) KRAS and CCND1 protein levels were assessed by Western blotting 48 hours after transfection. (E) The protein levels of p-ERK and p-Akt were evaluated by Western blotting 48 hours after miR-193b transfection.
Human Colon Cancer Cell Lines Skco1 (Kras Mutant), supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kras+mutant+cancer+cell+lines/pmc05133992-106-19-26?v=China+Center+for+Type+Culture+Collection
Average 90 stars, based on 1 article reviews
human colon cancer cell lines skco1 (kras mutant) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
kras g12d homozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have two alleles with G12D mutation of KRAS and puromycin marker in intron 2 of KRAS for selection. This cell line can be
   Buy from Supplier
oncospot kras g13c/g13g heterozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have two alleles with G13C mutation of KRAS and puromycin marker in intron 2 of KRAS for selection. This cell line can be
   Buy from Supplier
oncospot kras g12c heterozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have two alleles with G12C mutation of KRAS and puromycin marker in intron 2 of KRAS for selection. This cell line can be
   Buy from Supplier
oncospot kras g13c/g13d heterozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have two alleles with G13C mutationof KRAS and puromycin marker in intron 2 of KRAS for selection. This cell line can be used
   Buy from Supplier
kras g13d homozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have two alleles with G13D mutation of KRAS and puromycin marker in intron 1 of KRAS for selection. This cell line can be
   Buy from Supplier
kras g13d heterozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have one alleles with G13D mutation of KRAS and puromycin marker in intron 1 of KRAS for selection, and the other allele with
   Buy from Supplier
kras g12d heterozygous hct116 cancer biomarker mutant cell line  (Genecopoeia)
N/A
This product is a HCT116 cell line genetically modified using CRISPR to have one allele with G12D mutation of KRAS and puromycin marker in intron 2 of KRAS for selection, and the other allele with
   Buy from Supplier

Image Search Results


(A) The TargetScan online database ( http://www.targetscan.org ) predicted KRAS as an miR-193b target. The site between 1074 and 1080 (boxed region), one of the two predicted miR-193b binding sites in the 3′-UTR of KRAS, is shown, highlighting the evolutionarily conservation among humans (hsa), the chimpanzees (Ptr), rhesus monkey (Mml), bushbaby (Oga), and treeshrew (Tbe). (B) The two miR-193b binding sites at positions 303 to 309 and 1074–1080 in the KRAS 3′-UTR, identified using the TargetScan online database ( http://www.targetscan.org ), are shown. Seed sequences were mutated as shown in the boxed regions. The wild-type or mutant constructs were inserted into the pGL3 vector directly downstream of the luciferase gene. (C) 293A cells were co-transfected with miR-193b or scrambled oligonucleotide, wild-type or mutant firefly luciferase constructs of the KRAS 3′-UTR segment containing miR-193b binding sites, and Renilla luciferase (endogenous control). Luciferase activity was measured 24 hours after transfection using the Dual-Luciferase Reporter Assay Systems. Renilla-normalized luciferase activity is expressed relative to that obtained for the scrambled oligonucleotide under each condition. WT, wild-type; Mut, mutant. (D) KRAS and CCND1 protein levels were assessed by Western blotting 48 hours after transfection. (E) The protein levels of p-ERK and p-Akt were evaluated by Western blotting 48 hours after miR-193b transfection.

Journal: PLoS ONE

Article Title: Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer

doi: 10.1371/journal.pone.0125515

Figure Lengend Snippet: (A) The TargetScan online database ( http://www.targetscan.org ) predicted KRAS as an miR-193b target. The site between 1074 and 1080 (boxed region), one of the two predicted miR-193b binding sites in the 3′-UTR of KRAS, is shown, highlighting the evolutionarily conservation among humans (hsa), the chimpanzees (Ptr), rhesus monkey (Mml), bushbaby (Oga), and treeshrew (Tbe). (B) The two miR-193b binding sites at positions 303 to 309 and 1074–1080 in the KRAS 3′-UTR, identified using the TargetScan online database ( http://www.targetscan.org ), are shown. Seed sequences were mutated as shown in the boxed regions. The wild-type or mutant constructs were inserted into the pGL3 vector directly downstream of the luciferase gene. (C) 293A cells were co-transfected with miR-193b or scrambled oligonucleotide, wild-type or mutant firefly luciferase constructs of the KRAS 3′-UTR segment containing miR-193b binding sites, and Renilla luciferase (endogenous control). Luciferase activity was measured 24 hours after transfection using the Dual-Luciferase Reporter Assay Systems. Renilla-normalized luciferase activity is expressed relative to that obtained for the scrambled oligonucleotide under each condition. WT, wild-type; Mut, mutant. (D) KRAS and CCND1 protein levels were assessed by Western blotting 48 hours after transfection. (E) The protein levels of p-ERK and p-Akt were evaluated by Western blotting 48 hours after miR-193b transfection.

Article Snippet: In PDAC cell lines, we found that miR-193b expression is higher in BxPC-3 cells bearing wild-type KRAS compared to the AsPC-1, MIA PaCa-2 and PANC-1 cells, which harbor mutant KRAS (mutation statuses were obtained from www.atcc.org and www.sanger.ac.uk ).

Techniques: Binding Assay, Mutagenesis, Construct, Plasmid Preparation, Luciferase, Transfection, Control, Activity Assay, Reporter Assay, Western Blot